{"id":411887,"date":"2025-11-13T13:30:00","date_gmt":"2025-11-13T12:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/dreamm-8-key-study-in-the-development-of-bcma-therapy-up-to-dreamm-14\/"},"modified":"2025-11-12T21:50:40","modified_gmt":"2025-11-12T20:50:40","slug":"dreamm-8-key-study-in-the-development-of-bcma-therapy-up-to-dreamm-14","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/dreamm-8-key-study-in-the-development-of-bcma-therapy-up-to-dreamm-14\/","title":{"rendered":"DREAMM-8: Key study in the development of BCMA therapy up to DREAMM-14"},"content":{"rendered":"\n

The DREAMM-8 data presented at this year’s ASCO provided robust evidence of the efficacy and tolerability of the BPd combination (belantamab mafodotin, pomalidomide and dexamethasone) for the treatment of recurrent and refractory multiple myeloma (RRMM) with HRCA (high-risk cytogenetics). BPd, which offers a viable alternative especially for patients with HRCA for whom cell therapies are not suitable, could establish itself as a second-line therapy in Switzerland in the medium term following its recent approval by Swissmedic – even if DREAMM-14 , in which the dosage itself is being studied for the first time, could offer an optimized benefit-risk profile for ocular side effects in RRMM patients. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

The DREAMM-8 data presented at this year’s ASCO provided robust evidence of the efficacy and tolerability of the BPd combination (belantamab mafodotin, pomalidomide and dexamethasone) for the treatment of recurrent……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":411890,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Multiple myeloma ","footnotes":"[{\"id\":\"47c4fb67-b024-4175-8a23-577eaa60a3e2\",\"content\":\"C = Calcium increase, R = Renal dysfunction, A = Anemia, B = Bone lesion)\"},{\"id\":\"df635557-d508-4f1b-b0fe-d05c3810c624\",\"content\":\"MMAF stands for monomethyllauristatin F, a cytotoxic molecule that inhibits cell division by destabilizing microtubules. It belongs to the family of auristatins, which were originally derived from the marine organism Dolabella auricularia. The linker is the biochemical connection between the antibody and the active substance MMAF. It ensures that the drug remains stable in the blood, but is released inside the target cell (e.g. myeloma cell) as soon as the conjugate is taken up. Belamaf uses a maleimidocaproyl linker that is protease-resistant, i.e. it is not easily broken down in the blood. \"},{\"id\":\"1967fab0-c9f2-44ee-a954-f7d6e9c624d1\",\"content\":\"Blenrep\\u00ae was initially approved for a limited period in Switzerland on 20.06.2022, but from 28.06.2023 the drug was no longer approved.\"},{\"id\":\"ad64f421-8735-43dd-b69c-4ad85b335a9c\",\"content\":\"www.swissmedic.ch\\\/swissmedic\\\/de\\\/home\\\/ueber-uns\\\/publikationen\\\/public-summary-swiss-par-
blenrep-02<\\\/a>\"},{\"id\":\"4bc46feb-c92d-4fac-8104-7e9097e54d40\",\"content\":\"Patients with newly diagnosed myeloma\"},{\"id\":\"02220856-7081-4eb3-9698-99b0a15c1df1\",\"content\":\"Index for grading the quality of life of patients with cancer\"}]"},"category":[11513,11353,11370,11548,11503],"tags":[14740,86205,86197,15015,86195,86202,86196,86199,86208,13830],"powerkit_post_featured":[],"class_list":["post-411887","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-hematology","category-oncology","category-rx-en","category-studies","tag-asco-en","tag-belantamab","tag-bpd-combination","tag-car-t-en","tag-dreamm","tag-dreamm-14","tag-dreamm-8","tag-hrca","tag-mafodot","tag-multiple-myeloma","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-11 19:00:36","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":411854,"slug":"dreamm-8-etude-cle-dans-le-developpement-de-la-therapie-bcma-jusqua-dreamm-14","post_title":"DREAMM-8 : \u00e9tude cl\u00e9 dans le d\u00e9veloppement de la th\u00e9rapie BCMA jusqu'\u00e0 DREAMM-14","href":"https:\/\/medizinonline.com\/fr\/dreamm-8-etude-cle-dans-le-developpement-de-la-therapie-bcma-jusqua-dreamm-14\/"},"it_IT":{"locale":"it_IT","id":411851,"slug":"dreamm-8-studio-chiave-nello-sviluppo-della-terapia-bcma-fino-a-dreamm-14","post_title":"DREAMM-8: studio chiave nello sviluppo della terapia BCMA fino a DREAMM-14","href":"https:\/\/medizinonline.com\/it\/dreamm-8-studio-chiave-nello-sviluppo-della-terapia-bcma-fino-a-dreamm-14\/"},"pt_PT":{"locale":"pt_PT","id":411856,"slug":"dreamm-8-estudo-chave-no-desenvolvimento-da-terapia-bcma-ate-ao-dreamm-14","post_title":"DREAMM-8: Estudo-chave no desenvolvimento da terapia BCMA at\u00e9 ao DREAMM-14","href":"https:\/\/medizinonline.com\/pt-pt\/dreamm-8-estudo-chave-no-desenvolvimento-da-terapia-bcma-ate-ao-dreamm-14\/"},"es_ES":{"locale":"es_ES","id":411888,"slug":"dreamm-8-estudio-clave-en-el-desarrollo-de-la-terapia-bcma-hasta-el-dreamm-14","post_title":"DREAMM-8: Estudio clave en el desarrollo de la terapia BCMA hasta el DREAMM-14","href":"https:\/\/medizinonline.com\/es\/dreamm-8-estudio-clave-en-el-desarrollo-de-la-terapia-bcma-hasta-el-dreamm-14\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=411887"}],"version-history":[{"count":3,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411887\/revisions"}],"predecessor-version":[{"id":411903,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411887\/revisions\/411903"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/411890"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=411887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=411887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=411887"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=411887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}